Fewer Mycophenolate Adverse Events in Scleroderma Lung StudyFewer Mycophenolate Adverse Events in Scleroderma Lung Study

Results from the first clinical trial comparing mycophenolate with cyclophosphamide suggest that treatment options for scleroderma-related interstitial lung disease are expanding. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news